NO311635B1 - Vandig legemiddelpreparat med evne til reversibel varmeherdende gel - Google Patents

Vandig legemiddelpreparat med evne til reversibel varmeherdende gel Download PDF

Info

Publication number: NO311635B1
Authority: NO; Norway
Prior art keywords: agents; agent; hydrochloride; preparation; preparation according
Prior art date: 1993-04-16

Application number

NO19953189A

Other languages

English (en)

Norwegian (no)

Other versions

NO953189D0 (no

NO953189L (no

Inventor

Masanobu Takeuchi

Hiroe Suzuki

Toshie Takahashi

Hiroki Maruyama

Miyako Sasaki

Keiko Naitou

Touru Oguma

Masayoshi Goto

Original Assignee

Wakamoto Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-04-16

Filing date

1995-08-14

Publication date

2001-12-27

1995-08-14 Application filed by Wakamoto Pharma Co Ltd filed Critical Wakamoto Pharma Co Ltd

1995-08-14 Publication of NO953189D0 publication Critical patent/NO953189D0/no

1995-08-14 Publication of NO953189L publication Critical patent/NO953189L/no

2001-12-27 Publication of NO311635B1 publication Critical patent/NO311635B1/no

Links

239000003814 drug Substances 0.000 title claims abstract description 31
238000002360 preparation method Methods 0.000 title claims description 82
229940079593 drug Drugs 0.000 title claims description 30
230000002441 reversible effect Effects 0.000 title claims description 6
238000013007 heat curing Methods 0.000 title 1
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 45
239000000203 mixture Substances 0.000 claims abstract description 31
229920000609 methyl cellulose Polymers 0.000 claims abstract description 24
239000001923 methylcellulose Substances 0.000 claims abstract description 23
229920001223 polyethylene glycol Polymers 0.000 claims abstract description 16
239000002202 Polyethylene glycol Substances 0.000 claims abstract description 15
238000003745 diagnosis Methods 0.000 claims abstract description 4
239000003795 chemical substances by application Substances 0.000 claims description 20
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 16
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 10
229940121363 anti-inflammatory agent Drugs 0.000 claims description 9
239000002260 anti-inflammatory agent Substances 0.000 claims description 9
229960004393 lidocaine hydrochloride Drugs 0.000 claims description 9
YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 claims description 9
239000007788 liquid Substances 0.000 claims description 9
239000003589 local anesthetic agent Substances 0.000 claims description 9
229960000905 indomethacin Drugs 0.000 claims description 8
-1 methoxyl groups Chemical group 0.000 claims description 8
239000007864 aqueous solution Substances 0.000 claims description 7
229960001180 norfloxacin Drugs 0.000 claims description 7
OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 7
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 6
239000002256 antimetabolite Substances 0.000 claims description 6
229960000686 benzalkonium chloride Drugs 0.000 claims description 6
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 6
229960002949 fluorouracil Drugs 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 claims description 5
MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 claims description 5
239000000730 antalgic agent Substances 0.000 claims description 5
239000000739 antihistaminic agent Substances 0.000 claims description 5
VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 5
229960003957 dexamethasone Drugs 0.000 claims description 5
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 5
229960003276 erythromycin Drugs 0.000 claims description 5
229960005040 miconazole nitrate Drugs 0.000 claims description 5
239000003755 preservative agent Substances 0.000 claims description 5
WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 claims description 4
DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims description 4
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 4
229910002651 NO3 Inorganic materials 0.000 claims description 4
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 4
TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 claims description 4
POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 4
239000003242 anti bacterial agent Substances 0.000 claims description 4
229940125715 antihistaminic agent Drugs 0.000 claims description 4
CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 claims description 4
229940046978 chlorpheniramine maleate Drugs 0.000 claims description 4
229960004022 clotrimazole Drugs 0.000 claims description 4
RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 4
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
238000009998 heat setting Methods 0.000 claims description 4
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
229960004716 idoxuridine Drugs 0.000 claims description 4
229960003630 ketotifen fumarate Drugs 0.000 claims description 4
YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 claims description 4
229960005015 local anesthetics Drugs 0.000 claims description 4
239000003002 pH adjusting agent Substances 0.000 claims description 4
229960003101 pranoprofen Drugs 0.000 claims description 4
NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims description 4
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
239000002904 solvent Substances 0.000 claims description 4
238000002560 therapeutic procedure Methods 0.000 claims description 4
229960005221 timolol maleate Drugs 0.000 claims description 4
CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims description 3
DDVAZOPRCKAYOV-UHFFFAOYSA-N 2-(5-thiophen-3-yltetrazol-1-yl)acetic acid Chemical compound OC(=O)CN1N=NN=C1C1=CSC=C1 DDVAZOPRCKAYOV-UHFFFAOYSA-N 0.000 claims description 3
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 3
108010036949 Cyclosporine Proteins 0.000 claims description 3
229920000153 Povidone-iodine Polymers 0.000 claims description 3
208000017442 Retinal disease Diseases 0.000 claims description 3
206010038923 Retinopathy Diseases 0.000 claims description 3
BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 claims description 3
230000001919 adrenal effect Effects 0.000 claims description 3
150000001413 amino acids Chemical class 0.000 claims description 3
229960003556 aminophylline Drugs 0.000 claims description 3
FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 claims description 3
229940035676 analgesics Drugs 0.000 claims description 3
230000001437 anti-cataract Effects 0.000 claims description 3
230000003178 anti-diabetic effect Effects 0.000 claims description 3
230000001384 anti-glaucoma Effects 0.000 claims description 3
239000000043 antiallergic agent Substances 0.000 claims description 3
239000003472 antidiabetic agent Substances 0.000 claims description 3
239000004599 antimicrobial Substances 0.000 claims description 3
239000003908 antipruritic agent Substances 0.000 claims description 3
239000002221 antipyretic Substances 0.000 claims description 3
229940125716 antipyretic agent Drugs 0.000 claims description 3
229940124630 bronchodilator Drugs 0.000 claims description 3
229960001265 ciclosporin Drugs 0.000 claims description 3
229960000265 cromoglicic acid Drugs 0.000 claims description 3
229930182912 cyclosporin Natural products 0.000 claims description 3
229940039227 diagnostic agent Drugs 0.000 claims description 3
239000000032 diagnostic agent Substances 0.000 claims description 3
229960003529 diazepam Drugs 0.000 claims description 3
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 3
PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 claims description 3
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims description 3
VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 claims description 3
235000019162 flavin adenine dinucleotide Nutrition 0.000 claims description 3
239000011714 flavin adenine dinucleotide Substances 0.000 claims description 3
229940093632 flavin-adenine dinucleotide Drugs 0.000 claims description 3
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 3
229940020947 fluorescein sodium Drugs 0.000 claims description 3
210000004392 genitalia Anatomy 0.000 claims description 3
229940088597 hormone Drugs 0.000 claims description 3
239000005556 hormone Substances 0.000 claims description 3
239000003018 immunosuppressive agent Substances 0.000 claims description 3
239000003604 miotic agent Substances 0.000 claims description 3
239000002637 mydriatic agent Substances 0.000 claims description 3
230000002911 mydriatic effect Effects 0.000 claims description 3
229960001621 povidone-iodine Drugs 0.000 claims description 3
239000001488 sodium phosphate Substances 0.000 claims description 3
229960003339 sodium phosphate Drugs 0.000 claims description 3
229910000162 sodium phosphate Inorganic materials 0.000 claims description 3
BJORNXNYWNIWEY-UHFFFAOYSA-N tetrahydrozoline hydrochloride Chemical compound Cl.N1CCN=C1C1C2=CC=CC=C2CCC1 BJORNXNYWNIWEY-UHFFFAOYSA-N 0.000 claims description 3
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 3
229960004791 tropicamide Drugs 0.000 claims description 3
239000005526 vasoconstrictor agent Substances 0.000 claims description 3
239000011782 vitamin Substances 0.000 claims description 3
229940088594 vitamin Drugs 0.000 claims description 3
235000013343 vitamin Nutrition 0.000 claims description 3
229930003231 vitamin Natural products 0.000 claims description 3
150000003722 vitamin derivatives Chemical class 0.000 claims description 3
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 2
OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 claims description 2
CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 claims description 2
RPABDKTXMKOGKI-OYTUFZPASA-N 6-methyl-n-[2-[(2s,5s,8s,11s,14s,17s,20s,23s)-8,11,14,20-tetrakis(2-aminoethyl)-5-[(1r)-1-hydroxyethyl]-17,23-bis(2-methylpropyl)-3,6,9,12,15,18,21,24-octaoxo-1,4,7,10,13,16,19,22-octazacyclotetracos-2-yl]ethyl]octanamide Chemical compound CCC(C)CCCCC(=O)NCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC1=O RPABDKTXMKOGKI-OYTUFZPASA-N 0.000 claims description 2
GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 2
POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 2
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 claims description 2
108010024636 Glutathione Proteins 0.000 claims description 2
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
102000016943 Muramidase Human genes 0.000 claims description 2
108010014251 Muramidase Proteins 0.000 claims description 2
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 2
DJDFFEBSKJCGHC-UHFFFAOYSA-N Naphazoline Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 DJDFFEBSKJCGHC-UHFFFAOYSA-N 0.000 claims description 2
HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 claims description 2
UGGAILYEBCSZIV-ITJSPEIASA-N Siccanin Chemical compound C1CCC(C)(C)[C@@H]2CC[C@]3(C)OC4=CC(C)=CC(O)=C4[C@H]4[C@@H]3[C@@]21CO4 UGGAILYEBCSZIV-ITJSPEIASA-N 0.000 claims description 2
UGGAILYEBCSZIV-UHFFFAOYSA-N Siccanin Natural products C1CCC(C)(C)C2CCC3(C)OC4=CC(C)=CC(O)=C4C4C3C21CO4 UGGAILYEBCSZIV-UHFFFAOYSA-N 0.000 claims description 2
NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 claims description 2
229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
VWQZJJZGISNFOE-UHFFFAOYSA-N acitazanolast Chemical group OC(=O)C(=O)NC1=CC=CC(C2=NNN=N2)=C1 VWQZJJZGISNFOE-UHFFFAOYSA-N 0.000 claims description 2
229960000458 allantoin Drugs 0.000 claims description 2
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 2
229960003942 amphotericin b Drugs 0.000 claims description 2
230000001754 anti-pyretic effect Effects 0.000 claims description 2
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
229960002170 azathioprine Drugs 0.000 claims description 2
229960002206 bifonazole Drugs 0.000 claims description 2
230000003115 biocidal effect Effects 0.000 claims description 2
239000000168 bronchodilator agent Substances 0.000 claims description 2
229960004484 carbachol Drugs 0.000 claims description 2
AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 claims description 2
FYBXRCFPOTXTJF-UHFFFAOYSA-N carteolol hydrochloride Chemical compound [Cl-].N1C(=O)CCC2=C1C=CC=C2OCC(O)C[NH2+]C(C)(C)C FYBXRCFPOTXTJF-UHFFFAOYSA-N 0.000 claims description 2
229960002165 carteolol hydrochloride Drugs 0.000 claims description 2
229960005091 chloramphenicol Drugs 0.000 claims description 2
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 2
YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims description 2
229960003333 chlorhexidine gluconate Drugs 0.000 claims description 2
108700028201 colistinmethanesulfonic acid Proteins 0.000 claims description 2
229960003290 cortisone acetate Drugs 0.000 claims description 2
229960002104 cyanocobalamin Drugs 0.000 claims description 2
235000000639 cyanocobalamin Nutrition 0.000 claims description 2
239000011666 cyanocobalamin Substances 0.000 claims description 2
239000000850 decongestant Substances 0.000 claims description 2
229940124581 decongestants Drugs 0.000 claims description 2
229960001193 diclofenac sodium Drugs 0.000 claims description 2
229960000525 diphenhydramine hydrochloride Drugs 0.000 claims description 2
229960003072 epinephrine hydrochloride Drugs 0.000 claims description 2
229960001347 fluocinolone acetonide Drugs 0.000 claims description 2
FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims description 2
229960001048 fluorometholone Drugs 0.000 claims description 2
FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 claims description 2
229960003180 glutathione Drugs 0.000 claims description 2
229960000890 hydrocortisone Drugs 0.000 claims description 2
239000005554 hypnotics and sedatives Substances 0.000 claims description 2
229940005535 hypnotics and sedatives Drugs 0.000 claims description 2
229960001680 ibuprofen Drugs 0.000 claims description 2
229960003444 immunosuppressant agent Drugs 0.000 claims description 2
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
229960000318 kanamycin Drugs 0.000 claims description 2
229930027917 kanamycin Natural products 0.000 claims description 2
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 2
229930182823 kanamycin A Natural products 0.000 claims description 2
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 2
229960000991 ketoprofen Drugs 0.000 claims description 2
229960000274 lysozyme Drugs 0.000 claims description 2
239000004325 lysozyme Substances 0.000 claims description 2
235000010335 lysozyme Nutrition 0.000 claims description 2
230000003547 miosis Effects 0.000 claims description 2
229960000210 nalidixic acid Drugs 0.000 claims description 2
MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 claims description 2
229960004186 naphazoline nitrate Drugs 0.000 claims description 2
OSZNNLWOYWAHSS-UHFFFAOYSA-M neostigmine methyl sulfate Chemical compound COS([O-])(=O)=O.CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 OSZNNLWOYWAHSS-UHFFFAOYSA-M 0.000 claims description 2
229960002253 neostigmine methylsulfate Drugs 0.000 claims description 2
229960001699 ofloxacin Drugs 0.000 claims description 2
PRGUDWLMFLCODA-UHFFFAOYSA-N oxybuprocaine hydrochloride Chemical compound [Cl-].CCCCOC1=CC(C(=O)OCC[NH+](CC)CC)=CC=C1N PRGUDWLMFLCODA-UHFFFAOYSA-N 0.000 claims description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
229960002895 phenylbutazone Drugs 0.000 claims description 2
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims description 2
OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 claims description 2
229960003733 phenylephrine hydrochloride Drugs 0.000 claims description 2
229960001309 procaine hydrochloride Drugs 0.000 claims description 2
235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims description 2
239000011589 pyridoxal 5'-phosphate Substances 0.000 claims description 2
229960001327 pyridoxal phosphate Drugs 0.000 claims description 2
229960004889 salicylic acid Drugs 0.000 claims description 2
229950008379 siccanin Drugs 0.000 claims description 2
JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims description 2
229960000654 sulfafurazole Drugs 0.000 claims description 2
229960000894 sulindac Drugs 0.000 claims description 2
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims description 2
WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 claims description 2
229960001674 tegafur Drugs 0.000 claims description 2
229960000707 tobramycin Drugs 0.000 claims description 2
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 2
229960005294 triamcinolone Drugs 0.000 claims description 2
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 2
229940070710 valerate Drugs 0.000 claims description 2
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 2
230000000202 analgesic effect Effects 0.000 claims 3
206010061926 Purulence Diseases 0.000 claims 2
239000012678 infectious agent Substances 0.000 claims 2
RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 claims 2
229960002139 pilocarpine hydrochloride Drugs 0.000 claims 2
229930182566 Gentamicin Natural products 0.000 claims 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
230000001387 anti-histamine Effects 0.000 claims 1
229940088710 antibiotic agent Drugs 0.000 claims 1
239000002246 antineoplastic agent Substances 0.000 claims 1
239000003907 antipyretic analgesic agent Substances 0.000 claims 1
210000000467 autonomic pathway Anatomy 0.000 claims 1
239000000872 buffer Substances 0.000 claims 1
229960003669 carbenicillin Drugs 0.000 claims 1
RTYJTGSCYUUYAL-YCAHSCEMSA-L carbenicillin disodium Chemical compound [Na+].[Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)C(C([O-])=O)C1=CC=CC=C1 RTYJTGSCYUUYAL-YCAHSCEMSA-L 0.000 claims 1
229940006423 chondroitin sulfate sodium Drugs 0.000 claims 1
229940127089 cytotoxic agent Drugs 0.000 claims 1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 1
229960004949 glycyrrhizic acid Drugs 0.000 claims 1
239000003326 hypnotic agent Substances 0.000 claims 1
230000000147 hypnotic effect Effects 0.000 claims 1
230000001861 immunosuppressant effect Effects 0.000 claims 1
229940125721 immunosuppressive agent Drugs 0.000 claims 1
229940126601 medicinal product Drugs 0.000 claims 1
239000000932 sedative agent Substances 0.000 claims 1
229940125723 sedative agent Drugs 0.000 claims 1
JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims 1
235000010981 methylcellulose Nutrition 0.000 abstract description 22
230000036760 body temperature Effects 0.000 abstract description 8
230000000694 effects Effects 0.000 abstract description 3
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 abstract 1
230000009969 flowable effect Effects 0.000 abstract 1
239000000499 gel Substances 0.000 abstract 1
229960002900 methylcellulose Drugs 0.000 abstract 1
238000011422 pharmacological therapy Methods 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
239000000306 component Substances 0.000 description 14
239000003889 eye drop Substances 0.000 description 14
229940012356 eye drops Drugs 0.000 description 14
229960004106 citric acid Drugs 0.000 description 13
238000003756 stirring Methods 0.000 description 13
238000001816 cooling Methods 0.000 description 11
238000000034 method Methods 0.000 description 11
238000012360 testing method Methods 0.000 description 11
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 9
241000124008 Mammalia Species 0.000 description 9
241000283973 Oryctolagus cuniculus Species 0.000 description 9
229940057838 polyethylene glycol 4000 Drugs 0.000 description 9
229960004605 timolol Drugs 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
238000001879 gelation Methods 0.000 description 8
239000000243 solution Substances 0.000 description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 6
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
239000000825 pharmaceutical preparation Substances 0.000 description 6
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
230000007704 transition Effects 0.000 description 6
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 5
238000012546 transfer Methods 0.000 description 5
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
239000006172 buffering agent Substances 0.000 description 4
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
229960004926 chlorobutanol Drugs 0.000 description 3
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 3
239000000463 material Substances 0.000 description 3
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
229960002216 methylparaben Drugs 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
229960003415 propylparaben Drugs 0.000 description 3
229960000999 sodium citrate dihydrate Drugs 0.000 description 3
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 3
229920001187 thermosetting polymer Polymers 0.000 description 3
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 3
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
229940022663 acetate Drugs 0.000 description 2
235000011054 acetic acid Nutrition 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
229960002684 aminocaproic acid Drugs 0.000 description 2
230000037396 body weight Effects 0.000 description 2
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
239000004327 boric acid Substances 0.000 description 2
235000010338 boric acid Nutrition 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
239000003921 oil Substances 0.000 description 2
229920001983 poloxamer Polymers 0.000 description 2
238000011160 research Methods 0.000 description 2
239000012056 semi-solid material Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
239000008118 PEG 6000 Substances 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
239000004283 Sodium sorbate Substances 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
210000001742 aqueous humor Anatomy 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000002567 autonomic effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
229960001950 benzethonium chloride Drugs 0.000 description 1
UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
229940067596 butylparaben Drugs 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
210000003467 cheek Anatomy 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
229960000520 diphenhydramine Drugs 0.000 description 1
KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
210000000613 ear canal Anatomy 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
229940067107 phenylethyl alcohol Drugs 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
239000000344 soap Substances 0.000 description 1
229940083542 sodium Drugs 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
235000019250 sodium sorbate Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229960003080 taurine Drugs 0.000 description 1
RXDJVBXMOZKSHS-UHFFFAOYSA-N tetracene-5,12-dicarbaldehyde Chemical compound C1=CC=C2C=C3C(C=O)=C(C=CC=C4)C4=C(C=O)C3=CC2=C1 RXDJVBXMOZKSHS-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Materials For Medical Uses (AREA)
Compositions Of Macromolecular Compounds (AREA)
Thermotherapy And Cooling Therapy Devices (AREA)

NO19953189A 1993-04-16 1995-08-14 Vandig legemiddelpreparat med evne til reversibel varmeherdende gel NO311635B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP11234593		1993-04-16
PCT/JP1993/001636 WO1994023750A1 (en)	1993-04-16	1993-11-10	Reversible, thermally gelling water-base medicinal composition

Publications (3)

Publication Number	Publication Date
NO953189D0 NO953189D0 (no)	1995-08-14
NO953189L NO953189L (no)	1995-08-14
NO311635B1 true NO311635B1 (no)	2001-12-27

Family

ID=14584369

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19953189A NO311635B1 (no)	1993-04-16	1995-08-14	Vandig legemiddelpreparat med evne til reversibel varmeherdende gel

Country Status (17)

Country	Link
US (1)	US5624962A (xx)
EP (1)	EP0694310B1 (xx)
KR (1)	KR0162025B1 (xx)
CN (1)	CN1048393C (xx)
AT (1)	ATE189772T1 (xx)
AU (1)	AU668447B2 (xx)
CA (1)	CA2153234C (xx)
DE (1)	DE69327878T2 (xx)
DK (1)	DK0694310T3 (xx)
ES (1)	ES2141775T3 (xx)
FI (1)	FI112778B (xx)
HK (1)	HK1017805A1 (xx)
HU (1)	HU220864B1 (xx)
IL (1)	IL107626A (xx)
NO (1)	NO311635B1 (xx)
RU (1)	RU2108112C1 (xx)
WO (1)	WO1994023750A1 (xx)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6436425B1 (en)	1988-11-16	2002-08-20	Mdv Technologies, Inc.	Method and non-gelling composition for inhibiting post-surgical adhesions
US5346703A (en)	1990-08-07	1994-09-13	Mediventures, Inc.	Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5318780A (en) *	1991-10-30	1994-06-07	Mediventures Inc.	Medical uses of in situ formed gels
ATE281075T1 (de) *	1994-03-28	2004-11-15	Univ Columbia	Zusammensetzung zum inaktivieren von reizstoffen in flüssigkeiten
WO1996011672A1 (fr) *	1994-10-13	1996-04-25	Wakamoto Pharmaceutical Co., Ltd.	Preparation lyophilisee permettant d'obtenir une composition pharmaceutique a base d'eau se transformant de maniere reversible en gel sous l'effet de la chaleur
DE19511322C2 (de)	1995-03-28	1999-09-02	Mann Gerhard Chem Pharm Fab	Sterile Augengele mit einem Gehalt an mittelkettigen Triglyceriden und Verfahren zu deren Herstellung
US5843470A (en)	1995-10-06	1998-12-01	Mdv Technologies, Inc.	Method and composition for inhibiting post-surgical adhesions
CA2232855C (en) *	1997-04-10	2007-10-09	Roche Consumer Health (Worldwide) Sa	Pharmaceutical formulation
ES2284202T3 (es) *	1997-05-14	2007-11-01	Senju Pharmaceutical Co., Ltd.	Preparaciones acuosas en suspension con excelente redispersabilidad.
JP2001526246A (ja) *	1997-12-23	2001-12-18	アライアンス・ファーマスーティカル・コーポレイション	薬剤送達及び／又は癒着防止のための方法及び組成物
US6197347B1 (en)	1998-06-29	2001-03-06	Andrx Pharmaceuticals, Inc.	Oral dosage for the controlled release of analgesic
ES2155027B1 (es) *	1999-05-24	2001-12-01	Univ Pais Vasco	Geles para propositos multiples, reversibles y degradables.
WO2000076555A1 (en) *	1999-06-11	2000-12-21	Pro Duct Health, Inc.	Gel composition for filing a breast milk duct prior to surgical excision of the duct or other breast tissue
US20020061281A1 (en) *	1999-07-06	2002-05-23	Osbakken Robert S.	Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) *	1999-07-06	2003-06-10	Sinuspharma, Inc.	Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
JP2001158750A (ja) *	1999-12-02	2001-06-12	Lion Corp	眼科用組成物及び抗アレルギー薬の持続性向上方法
JP3450805B2 (ja) *	2000-08-08	2003-09-29	わかもと製薬株式会社	水性医薬組成物
US7420030B2 (en)	2000-09-08	2008-09-02	The Board Of Regents Of The University Of Texas System	Aminopeptidase A (APA) targeting peptides for the treatment of cancer
EP1328214A4 (en) *	2000-09-20	2009-07-29	Shahinian Lee Jr	NASAL, INHALABLE AND LOCAL OPHTHALMIC PREPARATIONS AND MEDICATIONS WITH SPONTANEOUS CONSERVATION
JP4820024B2 (ja) *	2001-01-10	2011-11-24	昭和薬品化工株式会社	局所麻酔用組成物
WO2003007979A1 (en) *	2001-07-18	2003-01-30	Board Of Regents, The University Of Texas System	An anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration
US20040048243A1 (en) *	2001-09-07	2004-03-11	Wadih Arap	Methods and compositions for in vitro targeting
US6846846B2 (en) *	2001-10-23	2005-01-25	The Trustees Of Columbia University In The City Of New York	Gentle-acting skin disinfectants
US7745425B2 (en) *	2002-02-07	2010-06-29	The Trustees Of Columbia University In The City Of New York	Non-irritating compositions containing zinc salts
US7879365B2 (en) *	2002-02-07	2011-02-01	The Trustees Of Columbia University In The City Of New York	Zinc salt compositions for the prevention of dermal and mucosal irritation
CA2475224C (en)	2002-02-07	2011-11-01	The Trustees Of Columbia University In The City Of New York	Zinc salt compositions for the prevention of mucosal irritation from spermicides and microbicides
KR20040084931A (ko) *	2002-02-22	2004-10-06	산텐 세이야꾸 가부시키가이샤	미립자 결막하 투여를 위한 약물 수송 시스템
US20030211173A1 (en) *	2002-05-08	2003-11-13	Veach Tom C.	Lubrication composition
JPWO2004026953A1 (ja) *	2002-09-18	2006-01-19	わかもと製薬株式会社	透明な可逆性熱ゲル化水性組成物
US7220431B2 (en) *	2002-11-27	2007-05-22	Regents Of The University Of Minnesota	Methods and compositions for applying pharmacologic agents to the ear
JP2004196787A (ja) *	2002-12-04	2004-07-15	Santen Pharmaceut Co Ltd	結膜下デポによるドラッグデリバリーシステム
WO2004052399A1 (ja) *	2002-12-10	2004-06-24	Showa Yakuhin Kako Co., Ltd.	局所麻酔用組成物
US20050085446A1 (en) *	2003-04-14	2005-04-21	Babu M.K. M.	Fluoroquinolone formulations and methods of making and using the same
JP4669960B2 (ja) *	2003-06-03	2011-04-13	株式会社メドレックス	局所麻酔薬を含有する口中用または咽頭部用製剤
CN101217870B (zh) *	2003-07-17	2011-10-12	纽约市哥伦比亚大学托管会	含有季铵化合物及精油和/或精油成分的协同组合的抗微生物组合物
CN1835735B (zh) *	2003-08-20	2010-05-12	参天制药株式会社	微粒眼球筋膜下给药的药物释放系统
FR2860718B1 (fr) *	2003-10-09	2006-02-24	Jean Pascal Conduzorgues	Nouvelle formulation et ses applications dans le domaines cosmetiques ou pharmaceutiques
EP1708668A1 (en) *	2004-01-15	2006-10-11	Oral Bioscience Pty. Limited	Oral anaesthetic gel
US7658947B2 (en) *	2004-06-25	2010-02-09	Kimberly-Clark Worldwide, Inc.	Thermo-gelling composition
JP2007277095A (ja) *	2004-07-02	2007-10-25	Wakamoto Pharmaceut Co Ltd	アジスロマイシン含有可逆性熱ゲル化水性組成物
US7459416B2 (en) *	2004-07-12	2008-12-02	Panasonic Corporation	Fluid bearing unit and spindle motor using the same
KR20070113284A (ko)	2005-03-10	2007-11-28	쓰리엠 이노베이티브 프로퍼티즈 캄파니	미생물 오염의 감소방법
JP4979258B2 (ja) *	2005-04-08	2012-07-18	ロート製薬株式会社	アシタザノラスト含有水性組成物
CN100463668C (zh) *	2005-05-09	2009-02-25	凌沛学	可逆性热凝胶化水性药物组合物
CN100430069C (zh) *	2005-07-28	2008-11-05	凌沛学	一种中药及其复方的可逆性热凝胶化水性药物组合物
JP5011118B2 (ja) *	2005-10-17	2012-08-29	興和株式会社	インドメタシンを含有する外用液剤
EA008737B1 (ru) *	2005-12-07	2007-08-31	Леонид Андреевич Кожемякин	Средство для профилактики и лечения конъюнктивитов и кератитов различной этиологии (варианты), способ его применения
US7759327B2 (en)	2006-01-06	2010-07-20	The Trustees Of Columbia University In The City Of New York	Compositions containing zinc salts for coating medical articles
US20070249546A1 (en) *	2006-04-22	2007-10-25	Sawaya Assad S	Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
US20070253909A1 (en) *	2006-05-01	2007-11-01	Medi-Flex, Inc.	Aqueous Antiseptic Solution and Compatible Cationic Dye for Staining Skin
US20080108674A1 (en) *	2006-05-01	2008-05-08	Enturia, Inc.	Cationic antiseptic and dye formulation
US20070254854A1 (en) *	2006-05-01	2007-11-01	Medi-Flex, Inc.	Aqueous Antiseptic Solution and Compatible Anionic Dye for Staining Skin
TW200808375A (en) *	2006-05-12	2008-02-16	Otsuka Pharma Co Ltd	Hydrogel suspension and manufacturing process thereof
EA014780B1 (ru) *	2007-01-05	2011-02-28	Промед Экспортс Пвт. Лтд.	Офтальмическая композиция
DE102007002073A1 (de) *	2007-01-09	2008-07-10	Matthias Habenicht	Mittel zur Pflege und antimikrobiellen Behandlung der Haut
CN101784287B (zh) *	2007-06-26	2013-04-24	若素制药株式会社	水性组合物
PT2193795E (pt) *	2007-08-29	2014-10-22	Wakamoto Pharma Co Ltd	Composição farmacêutica aquosa contendo latanoprost
WO2009074853A2 (en) *	2007-12-10	2009-06-18	Promed Research Centre	Ophthalmic composition comprising phenylephrine
US8030297B2 (en) *	2008-05-14	2011-10-04	Otonomy, Inc.	Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders
US10517839B2 (en) *	2008-06-09	2019-12-31	Cornell University	Mast cell inhibition in diseases of the retina and vitreous
TW201023912A (en) *	2008-12-05	2010-07-01	Alcon Res Ltd	Pharmaceutical suspension
KR20110123789A (ko) *	2009-03-03	2011-11-15	알콘 리서치, 리미티드	리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물
WO2010101989A1 (en) *	2009-03-03	2010-09-10	Alcon Research, Ltd.	PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
AU2010221369B2 (en) *	2009-03-03	2014-03-13	Alcon Research, Ltd.	Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
US8299079B2 (en)	2009-05-22	2012-10-30	Kaufman Herbert E	Preparations and methods for ameliorating or reducing presbyopia
US20100298335A1 (en) *	2009-05-22	2010-11-25	Kaufman Herbert E	Preparations and Methods for Ameliorating or Reducing Presbyopia
CN103079595B (zh)	2010-08-27	2015-11-25	若素制药株式会社	滴眼用水性组合物
TWI544922B (zh)	2011-05-19	2016-08-11	愛爾康研究有限公司	高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
WO2013169458A1 (en) *	2012-05-11	2013-11-14	Bausch & Lomb Incorporated	Pharmaceutical compositions and methods for treating, controlling, ameliorating, or reversing conditions of dry eye
RU2485939C1 (ru) *	2012-06-19	2013-06-27	Станислав Анатольевич Кедик	Офтальмологический препарат в виде глазных капель, содержащий дисульфирам и таурин
US10507245B2 (en) *	2012-07-19	2019-12-17	Luis Felipe Vejarano Restrepo	Ophthalmic formulation and method for ameliorating presbyopia
RU2517033C1 (ru) *	2013-03-05	2014-05-27	федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации	Композиция для комплексного лечения больных с первичной открытоугольной глаукомой и заболеваниями глазной поверхности
CN103239390B (zh) *	2013-05-15	2014-08-06	中国人民解放军第三军医大学第二附属医院	托吡卡胺眼用温度敏感原位凝胶及其制备方法
WO2015095634A1 (en) *	2013-12-20	2015-06-25	The Procter & Gamble Company	Stable liquid medication containing diphenhydramine
JP6714247B2 (ja) *	2017-10-06	2020-06-24	有限会社ジーエヌコーポレーション	尿道狭窄治療剤および尿道狭窄治療方法
WO2019230750A1 (ja) *	2018-05-29	2019-12-05	学校法人神野学園	外用組成物
US20220008336A1 (en) *	2018-11-26	2022-01-13	Aiviva Biopharma, Inc.	Pharmaceutical biodissolvable gels for drug delivery

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3311577A (en) *	1965-03-29	1967-03-28	Burton Parsons Chemicals Inc	Underwater contact lens solution
US4100271A (en) *	1976-02-26	1978-07-11	Cooper Laboratories, Inc.	Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4188373A (en) *	1976-02-26	1980-02-12	Cooper Laboratories, Inc.	Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
DE2714065A1 (de) *	1977-03-30	1978-10-12	Boehringer Mannheim Gmbh	Instillationszubereitung
US4474752A (en) *	1983-05-16	1984-10-02	Merck & Co., Inc.	Drug delivery system utilizing thermosetting gels
US4474753A (en) *	1983-05-16	1984-10-02	Merck & Co., Inc.	Topical drug delivery system utilizing thermosetting gels
US4474751A (en) *	1983-05-16	1984-10-02	Merck & Co., Inc.	Ophthalmic drug delivery system utilizing thermosetting gels
US4478822A (en) *	1983-05-16	1984-10-23	Merck & Co., Inc.	Drug delivery system utilizing thermosetting gels
FR2588189B1 (fr) *	1985-10-03	1988-12-02	Merck Sharp & Dohme	Composition pharmaceutique de type a transition de phase liquide-gel
GB2203039B (en) *	1987-03-02	1990-10-24	American Cyanamid Co	Stable ophthalmic preparations containing acetazolamide
US5252318A (en) *	1990-06-15	1993-10-12	Allergan, Inc.	Reversible gelation compositions and methods of use
US5077033A (en) *	1990-08-07	1991-12-31	Mediventures Inc.	Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
MX9200339A (es) *	1991-01-28	1992-08-01	Hoechst Ag	Preparado para la liberacion controlada de sustancias activas, que son apropiadas como terapeuticos o para mejorar el crecimiento y el aprovechamiento de los piensos en rumiantes
AU679937B2 (en) *	1992-11-18	1997-07-17	Johnson & Johnson Consumer Products, Inc.	Extrudable compositions for topical or transdermal drug delivery

1993
- 1993-11-10 EP EP93924801A patent/EP0694310B1/en not_active Expired - Lifetime
- 1993-11-10 AU AU54333/94A patent/AU668447B2/en not_active Expired
- 1993-11-10 KR KR1019950703156A patent/KR0162025B1/ko not_active IP Right Cessation
- 1993-11-10 AT AT93924801T patent/ATE189772T1/de not_active IP Right Cessation
- 1993-11-10 DK DK93924801T patent/DK0694310T3/da active
- 1993-11-10 DE DE69327878T patent/DE69327878T2/de not_active Expired - Lifetime
- 1993-11-10 RU RU95122560A patent/RU2108112C1/ru not_active IP Right Cessation
- 1993-11-10 HU HU9502086A patent/HU220864B1/hu not_active IP Right Cessation
- 1993-11-10 CA CA002153234A patent/CA2153234C/en not_active Expired - Fee Related
- 1993-11-10 WO PCT/JP1993/001636 patent/WO1994023750A1/ja active IP Right Grant
- 1993-11-10 US US08/397,064 patent/US5624962A/en not_active Expired - Lifetime
- 1993-11-10 ES ES93924801T patent/ES2141775T3/es not_active Expired - Lifetime
- 1993-11-15 CN CN93121431A patent/CN1048393C/zh not_active Expired - Lifetime
- 1993-11-16 IL IL107626A patent/IL107626A/xx not_active IP Right Cessation
1995
- 1995-07-26 FI FI953575A patent/FI112778B/fi not_active IP Right Cessation
- 1995-08-14 NO NO19953189A patent/NO311635B1/no not_active IP Right Cessation
1998
- 1998-12-08 HK HK98112925A patent/HK1017805A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
US5624962A (en)	1997-04-29
DK0694310T3 (da)	2000-06-05
IL107626A0 (en)	1994-02-27
FI953575A0 (fi)	1995-07-26
DE69327878T2 (de)	2000-06-15
CN1048393C (zh)	2000-01-19
EP0694310B1 (en)	2000-02-16
AU668447B2 (en)	1996-05-02
IL107626A (en)	1997-09-30
EP0694310A4 (en)	1996-04-24
CN1097593A (zh)	1995-01-25
WO1994023750A1 (en)	1994-10-27
CA2153234A1 (en)	1994-10-27
ES2141775T3 (es)	2000-04-01
HU9502086D0 (en)	1995-09-28
DE69327878D1 (de)	2000-03-23
RU2108112C1 (ru)	1998-04-10
HK1017805A1 (en)	1999-11-26
FI112778B (fi)	2004-01-15
KR0162025B1 (ko)	1998-12-01
AU5433394A (en)	1994-11-08
NO953189D0 (no)	1995-08-14
ATE189772T1 (de)	2000-03-15
HUT71676A (en)	1996-01-29
KR960700075A (ko)	1996-01-19
EP0694310A1 (en)	1996-01-31
FI953575A (fi)	1995-07-26
CA2153234C (en)	1999-02-16
HU220864B1 (en)	2002-06-29
NO953189L (no)	1995-08-14

Publication	Publication Date	Title
NO311635B1 (no)	2001-12-27	Vandig legemiddelpreparat med evne til reversibel varmeherdende gel
US7612115B2 (en)	2009-11-03	Aqueous pharmaceutical compositions
RU95122560A (ru)	1998-02-10	Водная лекарственная композиция, обладающая свойством обратимого терморегулируемого гелеобразования
US20200197336A1 (en)	2020-06-25	Ketorolac tromethamine compositions for treating or preventing ocular pain
US20060188576A1 (en)	2006-08-24	Pirenzepine ophthalmic gel
NO314434B1 (no)	2003-03-24	Lav-viskositets oftalmisk blanding
NO314435B1 (no)	2003-03-24	Lav-viskositets oftalmisk blanding
WO2005042026A1 (ja)	2005-05-12	可逆性熱ゲル化水性組成物
WO2011018800A2 (en)	2011-02-17	A novel in-situ gel forming solution for ocular drug delivery
CN100463668C (zh)	2009-02-25	可逆性热凝胶化水性药物组合物
EA030535B1 (ru)	2018-08-31	Не содержащий консерванта офтальмологический фармацевтический состав
CN101977630A (zh)	2011-02-16	眼药组合物
CN103977011B (zh)	2017-04-19	含有曲伏前列素和噻吗洛尔的眼用凝胶剂及其制备方法
JP2729859B2 (ja)	1998-03-18	可逆性熱ゲル化水性医薬組成物
JP6672512B2 (ja)	2020-03-25	一酸化窒素放出プロスタミドを含有する眼科用組成物
US20070059274A1 (en)	2007-03-15	Ophthalmic compositions containing a PVA/borate gelling system
JP2023038930A (ja)	2023-03-17	眼表面薬物滞留化剤およびこれを含む点眼剤、並びに、これらの剤を用いた眼表面薬物滞留方法および眼科疾患治療方法
WO1997033562A1 (en)	1997-09-18	Ophthalmological composition of the type which undergoes liquid-gel phase transition
JP3504656B2 (ja)	2004-03-08	水性医薬組成物
CN110200904A (zh)	2019-09-06	一种降眼压缓释滴眼组合物及其制备方法
US20120028947A1 (en)	2012-02-02	Ophthalmic Compositions
WO2004026953A1 (ja)	2004-04-01	透明な可逆性熱ゲル化水性組成物
Singh	2006	2³-Factorial Design Studies to Optimize the Ophthalmic Drug Delivery

Legal Events

Date	Code	Title	Description
2011-06-27	MM1K	Lapsed by not paying the annual fees